#South Korea #Seoul #Seegene #Nature Awards #MDx Impact

Launch of the Nature Awards MDx Impact Grants 2025-2026

Seegene Inc., a leader in molecular diagnostics, in partnership with Springer Nature, has kicked off the call for applications for the Nature Awards MDx Impact Grants for the 2025-2026 cycle. This initiative specifically addresses a pressing public health issue: antibiotic resistance in urinary tract infections (UTIs).

Focus of the Program

The current round of grants places a spotlight on combating antibiotic resistance, a challenge that is becoming increasingly urgent globally. Esteemed researchers from all corners of the world are encouraged to submit proposals that focus on developing diagnostic solutions aimed at identifying various antibiotic resistance genes associated with UTIs.

As part of this program, candidates can propose clinical development ideas using up to 18 resistance genes as targets. Those selected will have the opportunity to secure a funding grant of up to $600,000 and gain access to Seegene’s diagnostic technologies, including PCR instruments and various associated software.

Goals of the Initiative

The drive behind the Nature Awards MDx Impact Grants is to foster innovation in medical diagnostics. Richard Hughes, Vice President at Springer Nature, emphasized the company’s goal to connect scientists and broaden the impact of innovative research. By supporting researchers in creating diagnostic solutions, the initiative aims to significantly enhance global healthcare.

Dr. Jik Young Park, Vice President and Head of R&D at Seegene, stated that this collaboration is vital in providing scientists with the necessary tools to transition novel ideas into actionable solutions. The partnership with Springer aims to facilitate the global research efforts, thereby progressing towards the goal of a world free from diseases.

Previous Cycles and Future Aspirations

This call for applications marks the third cycle of the Nature Awards MDx Impact Grants, which has seen past initiatives focus on the rapid detection of ViruResist Klebsiella pneumoniae and other innovative multiplex PCR tests for vulnerable patient groups.

The 2024-2025 cycle already demonstrated success in facilitating important research in the field of diagnostics and aims to continue advocating for practical implementation in clinical settings.

Seegene's established history in molecular diagnostics spans over 20 years, showcasing its expertise in the research, development, and commercialization of real-time syndromic PCR technologies. During the COVID-19 pandemic, Seegene distributed over 340 million tests to more than 100 countries, reinforcing its commitment to addressing health challenges on a global scale.

Technology and Innovation

An integral aspect of Seegene’s technological offering is its proprietary multiplex PCR capabilities, which allow for the simultaneous detection of up to 14 pathogens responsible for similar symptoms in a single test. This technology not only identifies co-infections but also provides crucial quantitative data for managing complex infections.

Through its technology-sharing initiative, Seegene collaborates with global institutions and experts to develop localized diagnostic products tailored to meet region-specific health challenges. This collaborative approach is pivotal in driving advancements and achieving their vision of a disease-free world.

Conclusion

The Nature Awards MDx Impact Grants represent a significant step towards enhancing global health initiatives through innovation in molecular diagnostics. Interested researchers should submit their applications by November 20, 2025, with winners expected to be announced in August 2026. For more information on applying, researchers can visit Seegene's website or follow their updates on LinkedIn.

With ongoing investments in research and technology, the partnership between Seegene and Springer Nature underscores their commitment to tackling some of the most pressing challenges in public health today.